A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma

Table 3 Sensitivity and specificity of measurements of fractionated plasma metanephrines

	Sensitivity (95% CI)*	Specificity (95% CI)*	Likelihood ratio of a positive test* (95% CI)*	Likelihood ratio of a negative test* (95% CI)*
ALL PATIENTS
Mayo Clinic†	96% (54/56) (88%, 99%)	85% (377/445) (81%, 88%)	6.31 (5.04, 7.90)	0.02 (0.00, 0.15)
NIH	99% (211/214) (96%, 100%)	89% (575/644) (87%, 91%)	9.20 (7.36, 11.51)	0.02 (0.01, 0.05)
Vienna	100% (17/17) (82%, 100%)	100% (14/14) (78%, 100%)	29.17 (1.91, 445.60)	0.03 (0.00, 0.44)
SPORADIC PATIENTS
Mayo Clinic	97% (38/39) (87%, 100%)	84% (335/399) (80%, 87%)	6.07 (4.83, 7.65)	0.03 (0.00, 0.21)
NIH	99% (137/138) (99%, 100%)	82% (249/305) (77%, 86%)	5.41 (4.27, 6.85)	0.01 (0.00, 0.06)
Vienna	100% (14/14) (79%, 100%)	100% (14/14) (79%, 100%)	29.00 (1.90, 443.27)	0.03 (0.00, 0.53)

*Calculated † 6 subjects without pheochromocytoma who had "interfering substances" noted upon measurement of the metanephrine fraction were excluded.

ISSN: 1472-6823